Cost-effectiveness of prolonged exposure therapy versus pharmacotherapy and treatment choice in posttraumatic stress disorder (the optimizing ptsd treatment trial): A doubly randomized preference trial

Journal of Clinical Psychiatry

Volumn 75, Issue 3, 2014, Pages 222-230

  Le, Quang A ^a   Doctor, Jason N ^a   Zoellner, Lori A ^a   Feeny, Norah C ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE;

ADULT; AGED; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG DOSE TITRATION; EUROQOL QUESTIONNAIRE 5 DIMENSIONS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT PREFERENCE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROLONGED EXPOSURE THERAPY; PSYCHOPHARMACOTHERAPY; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ADULT; COST-BENEFIT ANALYSIS; FEMALE; HEALTH SERVICES; HUMANS; IMPLOSIVE THERAPY; MALE; MIDDLE AGED; PATIENT PREFERENCE; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STRESS DISORDERS, POST-TRAUMATIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898718631     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.13m08719     Document Type: Article

References (39)

1. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52(12):1048-1060.
2. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. Clin Psychiatry. 1999;60(7):427-435.
3. Eibner C, Ringel JS, Kilmer B, et al. The cost of post-deployment mental health and cognitive conditions. In: Tanielian T, Jaycox LH, eds. Invisible Wounds of War: Psychological and Cognitive Injuries, Their Consequences, and Services to Assist Recovery. Santa Monica, CA: RAND; 2008.
4. Torgerson DJ, Sibbald B. Understanding controlled trials: what is a patient preference trial? BMJ. 1998;316(7128):360.
5. Long Q, Little RJ, Lin XH. Causal inference in hybrid intervention trials involving treatment choice. J Am StatAssoc. 2008;103(482):474-484.
6. Feeny NC, Zoellner LA. Anxiety treatment-new research findings for the clinician. Talk presented at: 2010 American Psychiatric Association Annual Meeting Symposium 12; May 22,2010; New Orleans, LA.
7. Youngstrom EA, Feeny NC, Zoellner LA, et al. Doubly randomized preference trial in PTSD-prolonged exposure versus sertraline (Symposium 5032). Talk presented at: American Psychological Association Annual Convention; August 3,2013; Honolulu, HI.
8. Foa E, Riggs DS, Dancu CV, et al. Reliability and validity of a brief instrument for assessing post-traumatic stress disorder. Trauma Stress. 1993;6(4):459-473.
9. Foa EB, Hembree EA, Dancu CV. Prolonged Exposure (PE) Manual-Revised Version. Philadelphia, PA: University of Pennsylvania; 2002.
10. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000;283(14):1837-1844.
11. Davidson J, Pearlstein T, Londborg P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J.Psshiatry. 2001;158(12):1974-1981.
12. Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J. Psshiatry.2001;158(12):1982-1988.
13. Kind P. Guidelines for value sets in economic and on-economic studies using EQ-5D. In: Brooks R, Rabin R, Charro FD, eds. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. Amsterdam, the Netherlands: Kluwer Academic Publishers; 2003:29-41.
14. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the Dl valuation model. Med Care. 2005;43(3):203-220.
15. Bureau of Labor Statistics. Consumer price index (CPI). http://www.bls.gov/cpi/. Accessed January 9,2014.
16. Sirey JA, Meyers BS, Teresi JA, et al. The Cornell Service Index as a measure of health service use. PsychiatrServ. 2005;56(12):1564-1569.
17. Bureau of Labor Statistics. May 2012 National Occupational Employment and Wage Estimates United States, http://www.bls.gov/oes/current/oes-nat.htm. Accessed January 9,2014.
18. Drug Topics Red Book. Montvale, NJ: Thomson Healthcare; 2012.
19. Stranges E, Levit K, Stocks C, et al. State Variation in Inpatient Hospitalizations for Mental Health and Substance Abuse Conditions, 2002-2008: Statistical Brief #117. Healthcare Cost and Utilization Project, http://www.hcup-us.ahrq. gov/reports/statbriefs/sb 117.pdf. Accessed January 9,2014.
20. Machlin S, Chowdhury S. Expenses and Characteristics of Physician Visits in Different Ambulatory Care Settings, 2008. Statistical Brief #318. Agency for Healthcare Research and Quality, Rockville, MD. http://meps.ahrq.gov/mepsweb/ data-files/publications/st318/stat318.shtml. Updated March 2011. Accessed January 9,2014.
21. Phibbs CS, Scott JY, Flores NE, et al. HERCs Outpatient Average Cost Data Sets for VA Care: Fiscal Years 2010 Update. Palo Alto, CA: Health Economics Resource Center; 2011. http://www.herc.research.va.gov/methods/methods-cost-ac. asp. Updated April 22,2013. Accessed January 9,2014.
22. Helvie CO. Efficacy of primary care in a nursing center. Nurs Case Manag. 1999;4(4):201-210.
23. Curtiss FR, Lettrich P, Fairman KA. What is the price benchmark to replace average wholesale price (AWP)? J Manag Care Pharm. 2010;16(7):492-501.
24. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518-528.
25. Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Earn. 2010;19(4):422-437.
26. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-342.
27. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637-1641.
28. Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349-356.
29. Glick H. Economic Evaluation in Clinical Trials. New York, NY: Oxford University Press; 2007.
30. Efron B, Tibshirani R. Cross-validation and other estimates of prediction error. In: Efron B, Tibshirani RJ, eds. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993.
31. Multiple imputation. STATA Reference Manual, Release 12. College Station, TX:Stata Press; 2011.
32. Walker EA, Katon W, Russo J, et al. Health care costs associated with posttraumatic stress disorder symptoms in women. Arch Gen Psychiatry. 2003;60(4):369-374.
33. Marciniak MD, Lage MJ, Dunayevich E, et al. The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depress Anxiety. 2005;21(4):178-184.
34. Mills KL, Teesson M, Ross J, et al. The costs and outcomes of treatment for opioid dependence associated with posttraumatic stress disorder. Psychiatr Serv. 2005;56(8):940-945.
35. Congressional Budget Office. The Veterans Health Administration's treatment of PTSD and traumatic brain injury among recent combat veterans: February 2012. http://www.cbo.gov/sites/default/files/cbofiles/attachments/02- 09-PTSD.pdf. Accessed January 9,2014.
36. Issakidis C, Sanderson K, Corry J, et al. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. Psychol Med. 2004;34(1):19-35.
37. Gospodarevskaya E, Segal L. Cost-utility analysis of different treatments for post-traumatic stress disorder in sexually abused children. Child Adolesc Psychiatry Ment Health. 2012;6(1):15.
38. Joesch JM, Sherbourne CD, Sullivan G, et al. Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care. Psychol Med. 2012;42(9):1937-1948.
39. Roy-Byrne P, Craske MG, Sullivan G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010;303(19):1921-1928.